SNO 2020: Larotrectinib Holds Promise in CNS Metastases of TRK Fusion Cancers
The drug was highly active and well tolerated in patients harboring such metastases.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.